Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
Since the outbreak of the COVID-19 pandemic, widespread infections have allowed SARS-CoV-2 to evolve in human, leading to the emergence of multiple circulating variants. Some of these variants show increased resistance to vaccines, convalescent plasma, or monoclonal antibodies. In particular, mutations in the SARS-CoV-2 spike have drawn attention. To facilitate the isolation of neutralizing antibodies and the monitoring the vaccine effectiveness against these variants, we designed and produced biotin-labeled molecular probes of variant SARS-CoV-2 spikes and their subdomains, using a structure-based construct design that incorporated an N-terminal purification tag, a specific amino acid sequence for protease cleavage, the variant spike-based region of interest, and a C-terminal sequence targeted by biotin ligase. These probes could be produced by a single step using in-process biotinylation and purification. We characterized the physical properties and antigenicity of these probes, comprising the N-terminal domain (NTD), the receptor-binding domain (RBD), the RBD and subdomain 1 (RBD-SD1), and the prefusion-stabilized spike ectodomain (S2P) with sequences from SARS-CoV-2 variants of concern or of interest, including variants Alpha, Beta, Gamma, Epsilon, Iota, Kappa, Delta, Lambda, Mu, and Omicron. We functionally validated probes by using yeast expressing a panel of nine SARS-CoV-2 spike-binding antibodies and confirmed sorting capabilities of variant probes using yeast displaying libraries of plasma antibodies from COVID-19 convalescent donors. We deposited these constructs to Addgene to enable their dissemination. Overall, this study describes a matrix of SARS-CoV-2 variant molecular probes that allow for assessment of immune responses, identification of serum antibody specificity, and isolation and characterization of neutralizing antibodies.
| Errataetall: |
UpdateIn: PLoS One. 2022 May 24;17(5):e0268767. - PMID 35609088 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2021) vom: 30. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Teng, I-Ting [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 05.04.2024 published: Electronic UpdateIn: PLoS One. 2022 May 24;17(5):e0268767. - PMID 35609088 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.12.29.474491 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335533752 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335533752 | ||
| 003 | DE-627 | ||
| 005 | 20240405232526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.29.474491 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM335533752 | ||
| 035 | |a (NLM)35018379 | ||
| 035 | |a (PII)2021.12.29.474491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Teng, I-Ting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: PLoS One. 2022 May 24;17(5):e0268767. - PMID 35609088 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Since the outbreak of the COVID-19 pandemic, widespread infections have allowed SARS-CoV-2 to evolve in human, leading to the emergence of multiple circulating variants. Some of these variants show increased resistance to vaccines, convalescent plasma, or monoclonal antibodies. In particular, mutations in the SARS-CoV-2 spike have drawn attention. To facilitate the isolation of neutralizing antibodies and the monitoring the vaccine effectiveness against these variants, we designed and produced biotin-labeled molecular probes of variant SARS-CoV-2 spikes and their subdomains, using a structure-based construct design that incorporated an N-terminal purification tag, a specific amino acid sequence for protease cleavage, the variant spike-based region of interest, and a C-terminal sequence targeted by biotin ligase. These probes could be produced by a single step using in-process biotinylation and purification. We characterized the physical properties and antigenicity of these probes, comprising the N-terminal domain (NTD), the receptor-binding domain (RBD), the RBD and subdomain 1 (RBD-SD1), and the prefusion-stabilized spike ectodomain (S2P) with sequences from SARS-CoV-2 variants of concern or of interest, including variants Alpha, Beta, Gamma, Epsilon, Iota, Kappa, Delta, Lambda, Mu, and Omicron. We functionally validated probes by using yeast expressing a panel of nine SARS-CoV-2 spike-binding antibodies and confirmed sorting capabilities of variant probes using yeast displaying libraries of plasma antibodies from COVID-19 convalescent donors. We deposited these constructs to Addgene to enable their dissemination. Overall, this study describes a matrix of SARS-CoV-2 variant molecular probes that allow for assessment of immune responses, identification of serum antibody specificity, and isolation and characterization of neutralizing antibodies | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Nazzari, Alexandra F |e verfasserin |4 aut | |
| 700 | 1 | |a Choe, Misook |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira de Souza, Matheus |e verfasserin |4 aut | |
| 700 | 1 | |a Petrova, Yuliya |e verfasserin |4 aut | |
| 700 | 1 | |a Tsybovsky, Yaroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shuishu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Baoshan |e verfasserin |4 aut | |
| 700 | 1 | |a Artamonov, Mykhaylo |e verfasserin |4 aut | |
| 700 | 1 | |a Madan, Bharat |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Aric |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez Acevedo, Sheila N |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Ruckwardt, Tracy J |e verfasserin |4 aut | |
| 700 | 1 | |a DeKosky, Brandon J |e verfasserin |4 aut | |
| 700 | 1 | |a Mascola, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Misasi, John |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, Nancy J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Tongqing |e verfasserin |4 aut | |
| 700 | 1 | |a Kwong, Peter D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2021) vom: 30. Dez. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.29.474491 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||